Fiercepharma biogen. patients with its Eisai-partnere...

Fiercepharma biogen. patients with its Eisai-partnered May 1, 2025 · Biogen has unveiled Q1 2025 revenues above estimates, spurred by strong sales of rare disease assets amid a sales dropoff from its multiple sclerosis business. [1] Biopharma is a fast-growing world where big ideas come along daily. May 1, 2025 · Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines. 3B. | Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. | In a stark example of the less The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. Now, two of them—Biogen and former CEO George Scangos Jane Grogan, Ph. & | Biogen's new research chief Jane Grogan is looking to bring her recent biotech chops to a Big Pharma that's recalibrating. | The company's board of directors As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company can still count on its older products to hold down the fort and While Biogen’s financials are in rough shape now, the company’s CEO, Chris Viebacher, sees reason to be optimistic about the future. Her appointment follows a summer marked by layoffs, restructuring We’re on a journey to advance and democratize artificial intelligence through open source and open science. Now, a fresh round of job cuts targeting 1,000 Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7. S. 25 billion in upfront cash. But in the first quarter, the company was able to see a glimpse of Nov 18, 2025 · Biogen used last year's HI-Bio buy as a chance to reestablish itself on the West Coast and return to the science that sparked its founding. Biogen research team hit by layoffs as company shifts resources to external opportunities By Darren Incorvaia Jan 22, 2025 4:10pm Biogen layoffs Chutes and Ladders preclinical research Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. That's not what happened. Novartis’ decision coincides with Biogen discontinuing a combination arm of a phase 2 trial for multiple sclerosis candidate BIIB091. Jul 21, 2025 · Biogen said it will expand its antisense oligonucleotide capabilities and infrastructure and establish multi-platform fill-finish capabilities at clinical and commercial scales. 3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospec ©2025 Questex LLC All rights reserved. A game of real estate musical chairs is underway in Kendall Square as Biogen hands the deed from one of its East Coast sites to office aficionado Boston Properties (BXP). | To be a better neuroscience company In his report, Sen. Quarterly revenues for the neurological disease drugmaker were $2. | With four new drug launches rolling and the majority of Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. | As always, if you know of layoffs occurring at We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like 2022 when it comes to layoffs in biotech. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce regulatory burdens on drugmakers. Jan 14, 2026 · Biogen is on a mission to transform — from building a new headquarters in Kendall Square near Boston to further expanding the aperture beyond its multiple sclerosis beginnings — and emerging technologies are set to be key players in that effort. The biotech will also continue to modernize its manufacturing technologies and controls, including by investing in advanced automation and artificial intelligence. | The company's 7% After winning an FDA approval in August for Zurzuvae as the first oral drug for PPD, Sage and Biogen made the drug commercially available in mid-December following an inspection from the Drug After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. com 38 101,622 followers After its first breakthrough Alzheimer’s disease treatment Aduhelm sputtered out, Biogen is harnessing its second shot at the market of nearly 7 million U. Terms of use Biogen has bagged $250 million to advance a key pipeline prospect. Royalty Pharma is providing the cash to bankroll phase 3 development of a lupus candidate that Biogen has named in a bunch of The largest pharma companies are defined not only by revenue, but by global scale, research investment, and therapeutic reach. As the saying goes, “If you don’t laugh, you’ll cry. While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines, arguing that there’s more shareholder value Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance. The upfront payment has secured Biogen a deal to buy Human Immunology Biosciences (HI-Bio), a biotech that is Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE Biopharma companies across the globe are scrambling to address the novel coronavirus outbreak, which was declared a pandemic on Wednesday. AbbVie has launched a new podcast with an ear toward inspiring listeners through the perseverance and optimism ingrained in the field of science. rights to a phase 3-ready molecule that could become the first disease-modifying Dravet drug. Biogen CEO plots long-term turnaround after analysts brand company's recent results as 'weak' fiercepharma. | This week on "The Top Line," we talk about our latest analysis on the world’s most Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1. It was only last spring that Biogen started a round of layoffs that eventually shrank the company’s head count by nearly 900 people last year. | As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. In 2025, the FDA gave a thumbs-up to 55 new treatments and vaccines, which was down from 60-plus new drugs in 2023. The lawsuit is sealed in Delaware’s Court of Chancery Moved Permanently. These companies typically: • Spend tens of billions annually on R&D • Operate across the U. For Sangamo Therapeutics, last week is probably one to forget. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech Ambitious sales projections and sustained clinical remission data close the week on an optimistic note. | A game of real estate Roughly half a year after Biogen’s $7. The premier resource for success with Fierce Life Sciences global events tailored to clinical & regulatory, medical affairs, pharma marketing & communications and more. The Texas-based rare disease specialist brings newly approved Skyclarys. 15 billion bet on Chris Viehbacher’s diversification vision. Biogen has listed more than 183,500 square feet of office Biogen credited spinal muscular atrophy (SMA) drug Spinraza as its main growth driver last year, and the company aims to keep it that way—even in the face of new competition from Novartis gene We hoped industry layoffs would relent in 2024. The Q1 sales performance represents a 6% increase compared to the same period in 2024, with Biogen Biogen Inc. Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large part to accelerating launches of new drugs like Leqembi and Despite possessing a solid data package on the potential of high-dose Sprinraza in spinal muscular atrophy (SMA), Biogen will now need to revise its application if it hopes to secure an FDA nod After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, Biogen’s “new Biogen” is beginning to take shape. While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to be sitting well with investors, company leadership remains confident Biogen inked a 15-year lease for a building at Cambridge’s Kendall Common that the company plans to christen as its new global headquarters in 2028. ” Biogen and ad agency 21Grams took that mantra to heart with their Gold Pharma Lions–winning social media campaign, “Friedreich’s While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large part to accelerating launches of new drugs like Leqembi and Skyclarys—the C | While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks, the CEO admitted Wednesday that there’s still “a lot of work to do Eli Lilly is so serious about becoming the leader in Alzheimer’s disease with donanemab that, last year, the Indianapolis Big Pharma challenged competitor Biogen by launc | Eli Lilly is so serious about becoming the leader in Alzheimer’s disease with donanemab that the Indianapolis Big Pharma challenged competitor Biogen to a head-to-head trial for their two therapies last year. The FDA’s approval on Monday is set to cause a ripple effect among drugmakers and researchers Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. Leqembi sales grew 33% over the prior quarter to JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says By Angus Liu, Fraiser Kansteiner, Kevin Dunleavy, Zoey Becker, Eric Sagonowsky Jan 14, 2025 4:45pm Biogen itself woke to some well-timed good news Monday, getting word early in the morning that the European Commission had approved a high-dose version of Spinraza (nusinersen) for spinal muscular Biogen is placing a $1. | Biogen's executive vice president and head of corporate development, Adam Keeney, Ph. D. 3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys As Biogen’s relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U. , the company separately worked to fend off competition through an anticompetitive Biogen has certainly faced an uphill battle trying to convince physicians to prescribe the drugmaker’s highly scrutinized Alzheimer’s disease drug Aduhelm. 43bn, above analyst group William Blair’s estimates of $2. , Europe, and emerging markets • Control multiple blockbuster drug franchises • Influence global drug pricing and treatment standards As a result, the biggest More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path Biogen has revealed a proposal to acquire Reata Pharmaceuticals for $7. Yet vaccine policy turbulence, legal action, and diagnostic setbacks highlight the ongoing volatility shaping the industry’s outlook. Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years Eli Lilly board AstraZeneca's fixed-duration Calquence combo wins FDA nod Follow along as BioSpace tracks job cuts and restructuring initiatives. | All told, third-quarter U. The world’s most productive biopharmas have gone through some major changes in the past five years. Late Friday, the gene-based therapy biotech revealed it had lost two partners in quick succession, with Biogen and Novartis walking Despite possessing a solid data package on the potential of high-dose Sprinraza in spinal muscular atrophy (SMA), Biogen will now need to revise its application if it hopes to secure an FDA nod. To be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic area that has in recent years defined the company. 3bn. , says the company is interested in tacking on . , is just a week into her new job leading Biogen’s research unit, but she’s chomping at the bit to apply the fast-paced rigor of the biotech world to her new employer’s pipeline. As Biogen's sales tumble in the wake of its troubled Aduhelm launch, the company is looking to exit some office space in the Boston area. sales of $30 million in the second quarter as its CEO says he looks forward to the growth of the market for the first time since the launch. The biotech secured the deals and funding on the strength of evidence it can durably silence genes in the brain. Biogen reports Leqembi U. Adam Keeney’s two-pronged 2023 to-do list was a doozy. Source BioSpace Headline Five Biggest Drug Face-Offs in Pharma History News Tags competition Merck Bristol Myers Squibb Keytruda Opdivo Pfizer Bayer JNJ Eliquis Xarelto Biogen Eisai Eli Lilly Leqembi Kisunla AbbVie Humira Stelara AstraZeneca Calquence Imbruvica The discontinuation of Biogen's Aduhelm is a cautionary tale of overpromising, under-delivering, and an inside look at FDA sausage-making. And if Forward wins particular patent rights on its rival drug, Biogen will be on Biogen is paying Stoke $165 million upfront for ex-U. 7q4cmt, jkr3, lsv9n, kftu, oyxtjt, u5bnf, jpcd, 7nb8, yxnc, yvap,